Rosiglitazone, an Agonist of PPARγ, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2

PPARγ ligands inhibit the proliferation of non-small cell lung carcinoma (NSCLC) cells in vitro. The mechanisms responsible for this effect remain incompletely elucidated, but PPARγ ligands appear to inhibit the mammalian target of rapamycin (mTOR) pathway. We set out to test the hypothesis that PPA...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, ShouWei, Zheng, Ying, Roman, Jesse
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892639/
https://www.ncbi.nlm.nih.gov/pubmed/17597835
http://dx.doi.org/10.1155/2007/29632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892639/
https://www.ncbi.nlm.nih.gov/pubmed/17597835
http://dx.doi.org/10.1155/2007/29632

Ejemplares similares